Opioid REMS Continuing Medical Education - 05/13/2016
On July 9, 2012, the Food and Drug Administration (FDA) approved a risk evaluation and mitigation strategy (REMS) for extended-release (ER) and long-acting (LA) opioid medications. The Collaborative on REMS Education (CORE), a multidisciplinary collaboration of 10 Partners and three cooperating organizations, have designed a core curriculum based on needs assessment, practice gaps, clinical competencies, learner self-assessment, with shared tools, resources, and outcomes to meet the requirements of the FDA REMS Blueprint. This educational activity is a result of this collaboration and is intended to ensure that all physicians have the knowledge and skills they need to prescribe extended-release, long-acting opioid medications safely and effectively.
Due to this generous contribution from CORE, physicians have free access to education on how to achieve safe use of opioids:
2013-14 ER/LA Opioid REMS: Achieving Safe Use While Improving Patient Care
3 AMA ...